Quest Diagnostics (DGX) Soars 1.40% On Strong Earnings

Quest Diagnostics (DGX) surged to a record high today, with an intraday gain of 1.40%.

Quest Diagnostics Inc. reported a robust 12% revenue increase and reaffirmed its positive financial outlook for 2025, driven by strategic advancements. This strong financial performance has bolstered investor confidence in the company's future prospects.

Fitch has upgraded Quest Diagnostics' rating from 'BBB' to 'BBB+', indicating a stable outlook. This upgrade applies to the company's senior unsecured revolving facility and senior unsecured debt, reflecting the company's improved financial health and stability.

Piper Sandler has adjusted the price target for Quest Diagnostics from $180.00 to $200.00, reflecting optimism from analysts. This adjustment suggests that analysts are bullish on the company's future performance and expect its stock price to continue rising.